Roche has received FDA clearance for its Alzheimer’s blook biomarker blood test. Trontinemab, currently in phase 3 trials, was developed in collaboration with Eli Lilly and is designed to help assess early signs or Alzheimer’s as well as other causes on cognitive decline in patients over 55 years old.
Click here to read the entire article.
